| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/22/2007 | WO2007020075A1 Use of neuropilin-2 antagonists |
| 02/22/2007 | WO2007020012A1 A process for the preparation of perindopril erbumine |
| 02/22/2007 | WO2007019618A1 Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| 02/22/2007 | WO2006135385A3 Antagonizing interleukin-21 receptor activity |
| 02/22/2007 | WO2006134280A3 Mutated nucleotide sequences of the hepatitis c virus |
| 02/22/2007 | WO2006134190A3 Agents and methods based on the use of the eda domain of fibronectin |
| 02/22/2007 | WO2006128679A3 Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases |
| 02/22/2007 | WO2006092338A3 Tnf-alpha binding polypeptide , uses thereof and methods employing it |
| 02/22/2007 | WO2006088741A3 Procoagulants based on metal-chelating lipids |
| 02/22/2007 | WO2006086321A3 Antimicrobial hexapeptides |
| 02/22/2007 | WO2006066088A3 Methods for treating autoimmune disorders |
| 02/22/2007 | WO2006066065A3 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv |
| 02/22/2007 | WO2006065977A3 Antimicrobial peptides and methods of use |
| 02/22/2007 | WO2006063302A3 Variants of glycogen synthase kinase 3 and uses thereof |
| 02/22/2007 | WO2006063028A3 Immunostimulatory compositions and uses thereof |
| 02/22/2007 | WO2006058024A3 Cellular receptors used in the treatment of inflammatory disease |
| 02/22/2007 | WO2006047673A3 Mammalian genes involved in infection |
| 02/22/2007 | WO2006039488A3 Hcv ns3-ns4a protease inhibition |
| 02/22/2007 | WO2005120582A3 Compositions and methods for inhibiting expression of hypoxia-inducible genes |
| 02/22/2007 | WO2005089518A3 Uch-l1 expression and cancer therapy |
| 02/22/2007 | WO2005046646A3 Blister pack and solid dosage form comprising desmopressin |
| 02/22/2007 | WO2004094467A3 H. pylori antigens |
| 02/22/2007 | WO2004090103A8 Identification of novel nogo-receptors and methods related thereto |
| 02/22/2007 | WO2004058800A3 Mammalian cell culture processes for protein production |
| 02/22/2007 | WO2003073991A3 Methods to increase or decrease bone density |
| 02/22/2007 | US20070044166 P2Y4 Receptor transgenic and knockout non-human mammals |
| 02/22/2007 | US20070044163 Interferon gamma-like protein |
| 02/22/2007 | US20070043211 Mammalian transforming growth factor beta-9 |
| 02/22/2007 | US20070043210 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/22/2007 | US20070043208 Crystal structure of erythrocyte binding domain of EBA-175 |
| 02/22/2007 | US20070043206 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/22/2007 | US20070043000 Immunosuppresive effects of pteridine derivatives |
| 02/22/2007 | US20070042991 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 02/22/2007 | US20070042990 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/22/2007 | US20070042989 Novel 2'-C-methyl nucleoside derivatives |
| 02/22/2007 | US20070042985 Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
| 02/22/2007 | US20070042981 Use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 02/22/2007 | US20070042980 Gp131: methods and compositions for treating cancer |
| 02/22/2007 | US20070042969 Peptides such as Lacosamide with analgesic, an anticonvulsant, an antidepressant or an NMDA receptor antagonist |
| 02/22/2007 | US20070042968 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease |
| 02/22/2007 | US20070042967 Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
| 02/22/2007 | US20070042966 Inhibition of cell motility, angiogenesis, and metastasis |
| 02/22/2007 | US20070042965 Crystallized structure of type IV collagen NC1 domain hexamer |
| 02/22/2007 | US20070042964 Compositions and methods for modulating connexin hemichannels |
| 02/22/2007 | US20070042963 Therapeutic peptides |
| 02/22/2007 | US20070042962 Peptide dependent upregulation of telomerase expression |
| 02/22/2007 | US20070042961 Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| 02/22/2007 | US20070042960 Use of Zven human proteins as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis |
| 02/22/2007 | US20070042959 Thrombin-inhibiting peptides |
| 02/22/2007 | US20070042958 Immunoglobulins; myostatins; for treatment of neuronal diseases, muscle and bone conditions, and metabolic disorders; improved solubility, pharmacokinetics |
| 02/22/2007 | US20070042957 Type v phosphodiesterase inhibitors and natriuretic polypeptides |
| 02/22/2007 | US20070042956 Novel GLP-1 compounds |
| 02/22/2007 | US20070042955 Abuse-resistant amphetamine prodrugs |
| 02/22/2007 | US20070042954 Soluble G-protein coupled receptors (sGPCR); corticotropin releasing factor receptor type 2 (sCRFR2) attached to affinity tag, fluorescent label, immunoglobulin domain or conjugated to polyoxyethylene glycol; skin, gastrointestinal, bipolar, and psychological disorders; drug abuse; anxiolytic agents |
| 02/22/2007 | US20070042953 Antiepileptogenic complex of albumin with docosahexaenoate |
| 02/22/2007 | US20070042952 Analogues of glp-1 |
| 02/22/2007 | US20070042951 Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| 02/22/2007 | US20070042950 Antagonistic analogs of gh rh (2003) |
| 02/22/2007 | US20070042949 Pharmaceutical compositions comprising an epitope of platelet gpiiia protein |
| 02/22/2007 | US20070042948 Vav inhibition in graft rejection |
| 02/22/2007 | US20070042947 Agents for preventing and/or treating uppper digestive tract disorders |
| 02/22/2007 | US20070042946 Peptide inhibitors of thrombin as potent anticoagulants |
| 02/22/2007 | US20070042945 Nouvelles compositions et methods de traitement du psoriasis |
| 02/22/2007 | US20070042944 purification of fibrinogen; loading a solution with fibrinogen and other proteins onto an immobilized metal ion affinity chromatography matrix under conditions such that the fibrinogen and the protein both bind to the matrix, and selectively eluting the fibrinogen; provide a lyophilized product |
| 02/22/2007 | US20070042943 Cyclosporin active, fatty acid triglyceride, glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10; immunosuppressant, anti inflammatory, anti parasitic |
| 02/22/2007 | US20070042942 Glycopeptide carboxy-saccharide derivatives |
| 02/22/2007 | US20070042941 Galectin 9-inducing factors |
| 02/22/2007 | US20070042940 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 02/22/2007 | US20070042939 Hepatitis C; antivirals; 8-modified,1', 2', 3' or 4'-branched purine nucleoside; treating HCV infection |
| 02/22/2007 | US20070042938 Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts |
| 02/22/2007 | US20070042937 Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| 02/22/2007 | US20070042936 glycerol cyclic pyruvate derivates; inhibit the binding of an immobilized D-proline derivative to serum amyloid P componen; amyloidosis; Alzheimers disease; maturity onset diabetes mellitus |
| 02/22/2007 | US20070042492 Amino acid sequences for transferring substances of interest from outside medium to inside of cells, specifically cell nuclei; useful for enhancing delivery of drugs into cytoplasm and/or the cell nucleus from the host organism being treated |
| 02/22/2007 | US20070042472 Mammalian transforming growth factor beta-9 |
| 02/22/2007 | US20070042471 Homogeneous preparations of il-28 and il-29 |
| 02/22/2007 | US20070042470 Homogeneous preparations of il-28 and il-29 |
| 02/22/2007 | US20070042469 Homogeneous preparations of IL-29 produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins which has antihepatitis activity |
| 02/22/2007 | US20070042467 NIMA interacting proteins |
| 02/22/2007 | US20070042465 Mammalian transforming growth factor beta-9 |
| 02/22/2007 | US20070042446 Drug screening; for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 02/22/2007 | US20070042437 Diagnosis and treatment of Alzheimer's Disease |
| 02/22/2007 | US20070042434 Method for identifying tff2 regulating agents and agents identified using said method |
| 02/22/2007 | US20070042428 Treatment of proliferative disorders |
| 02/22/2007 | US20070042420 Liver tumor marker sequences |
| 02/22/2007 | US20070042417 Use of a nucleic acid probe to detect Zven, a human protein that may inhibit Wnt, and is an agent that stimulates gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis |
| 02/22/2007 | US20070042416 Dendritic Enriched Secreted Lymphocyte Activation Molecule |
| 02/22/2007 | US20070042413 Platelet-derived growth factor D, DNA coding therefor, and uses thereof |
| 02/22/2007 | US20070042409 Mammalian obestatin receptors |
| 02/22/2007 | US20070042403 Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
| 02/22/2007 | US20070042374 drug screening; obesity, diabetes mellitus, impaired glucose tolerance, arteriosclerosis, hypertension or hyperlipemia |
| 02/22/2007 | US20070042361 Human secreted proteins |
| 02/22/2007 | US20070042353 HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| 02/22/2007 | US20070042347 High throughput biological heart rate monitor that is molecularly determined |
| 02/22/2007 | US20070042344 Differentiation regulating agent containing gene which regulating differentiation from stem cells into natural killer cells as effective ingredient |
| 02/22/2007 | US20070042050 Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression |
| 02/22/2007 | US20070042048 Devices, Compositions and Methods for the Pulmonary Delivery of Aerosolized Medicaments |
| 02/22/2007 | US20070042040 Methods and compositions using gonadotropin hormone releasing hormone |
| 02/22/2007 | US20070042032 Self forming, thermodynamically stable liposomes and their applications |
| 02/22/2007 | US20070042029 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| 02/22/2007 | US20070042021 To provide macro-nutrients and micro-nutrient and which prevents and/or alleviates mucosal damage, good-tasting, promotes weight gain; casein and whey proteins, TGF- beta and free glutamine |